©The Author(s) 2023. Published by Baishideng Publishing Group Inc. All rights reserved.
World J Diabetes. Sep 15, 2023; 14(9): 1385-1392
Published online Sep 15, 2023. doi: 10.4239/wjd.v14.i9.1385
Published online Sep 15, 2023. doi: 10.4239/wjd.v14.i9.1385
Effects of paricalcitol combined with hemodiafiltration on bone-metabolism-related indexes in patients with diabetic nephropathy and chronic renal failure
Xiao-Ying Ma, Yu-Ping Sheng, Xing-Meng Yang, Hao-Ran Zhang, Fu-Yun Sun, Department of Nephrology, Cangzhou Central Hospital, Cangzhou 061000, Hebei Province, China
Author contributions: Ma XY designed and performed the research and wrote the paper; Sun FY designed the research and supervised the report; Sheng YP and Yang XM designed the research and contributed to the analysis; Zhang HR provided clinical advice.
Institutional review board statement: The study was reviewed and approved by the Cangzhou Central Hospital.
Informed consent statement: All participants have signed an informed consent form.
Conflict-of-interest statement: The authors declare no conflicts of interest for this article.
Data sharing statement: Clinical data for this study can be obtained from the corresponding author.
Corresponding author: Fu-Yun Sun, MM, Professor, Department of Nephrology, Cangzhou Central Hospital, No. 16 Xinhua West Road, Yunhe District, Cangzhou 061000, Hebei Province, China. 17734498766@163.com
Received: May 4, 2023
Peer-review started: May 4, 2023
First decision: May 15, 2023
Revised: May 25, 2023
Accepted: August 7, 2023
Article in press: August 7, 2023
Published online: September 15, 2023
Processing time: 132 Days and 3.8 Hours
Peer-review started: May 4, 2023
First decision: May 15, 2023
Revised: May 25, 2023
Accepted: August 7, 2023
Article in press: August 7, 2023
Published online: September 15, 2023
Processing time: 132 Days and 3.8 Hours
Core Tip
Core Tip: This study confirmed that paricalcitol combined with hemodiafiltration can effectively improve the condition of patients with diabetic nephropathy (DN) and chronic renal failure (CRF) and alleviate calcium–phosphorus metabolism disorder. This study has also successfully constructed a predictive model. It provides a new reference for evaluating the efficacy of treatment of combined DN and CRF.